← Back to headlines
Gilead Sciences Acquires Arcellx for $7.8 Billion
Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.
23 Feb, 11:30 — 23 Feb, 11:40
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
cnbc
Center
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
cnbcMostly Factual57d ago
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Read full article →seeking-alphaMixed57d ago
M&A Snapshot: Gilead acquires Arcellx for $7.8B
Read full article →Coverage Timeline
First report: seeking-alpha · 23 Feb, 11:30|Full coverage: 2 · 10m|Window: 10m
Left-leaningCenterRight-leaning
